NO20032531L - Tetralon-derivater som antitumormidler - Google Patents

Tetralon-derivater som antitumormidler

Info

Publication number
NO20032531L
NO20032531L NO20032531A NO20032531A NO20032531L NO 20032531 L NO20032531 L NO 20032531L NO 20032531 A NO20032531 A NO 20032531A NO 20032531 A NO20032531 A NO 20032531A NO 20032531 L NO20032531 L NO 20032531L
Authority
NO
Norway
Prior art keywords
alkyl
amino
hydrogen
compounds
alkylene chain
Prior art date
Application number
NO20032531A
Other languages
English (en)
Other versions
NO20032531D0 (no
Inventor
Guy Georges
Adelbert Grossmann
Tim Sattelkau
Wolfgang Schaefer
Ulrich Tibes
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20032531D0 publication Critical patent/NO20032531D0/no
Publication of NO20032531L publication Critical patent/NO20032531L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forbindelser med formel (1) hvor RI, R,2, R3, R4, R5, X og Y har betydningene angitt nedenfor, fremgangsmåte for fremstilling av disse forbindelser og farmasøytiske midler inneholdende en slik forbindelse har HDAC-inhibitoraktivitet. RI er valgt fra hydrogen, (1-4)alkyl, COOH, COO(l-4C)alkyl, R2, R3, R4, R5 uavhengig er valgt fra hydrogen, et halogenatom, en 1 -4C)alkyl-, trifluormetyl-, hydroksy-, (1 -4C)alkoksy-. aryloksy-, arylalkyloksy-, nitro-, amino-, (l-4C)alkylamino-, di[(l-4C)alkyl]-amino-, piperidino, morfolino, pyrrolidino, (1 -4C)alkanoylamino- eller en arylgruppe eller en heteroarylgruppe, eller henholdsvis R2 og R3 sammen eller R3 og R4 sammen eller R4 og R5 sammen kan danne en (1 -3C)alkylendioksyring, eller henholdsvis R2 og R3 sammen eller R3 og R4 sammen eller R4 og R5 sammen kan danne en (3-5C)alkylenkjede. Y er CH-CH-. X er en alkylenkjede med 4 til 10 karbonatomer som kan være mettet eller umettet med én eller to dobbeltbtndinger eller én eller to trippelbindinger eller én dobbelt- og én trippelbinding, og som kan være forgrenet eller rettkjedet eller avbrutt med en (3-7C)- cykloalkylring;
NO20032531A 2000-12-07 2003-06-04 Tetralon-derivater som antitumormidler NO20032531L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126820 2000-12-07
PCT/EP2001/014311 WO2002046144A1 (en) 2000-12-07 2001-12-06 Tetralone derivatives as antitumor agents

Publications (2)

Publication Number Publication Date
NO20032531D0 NO20032531D0 (no) 2003-06-04
NO20032531L true NO20032531L (no) 2003-06-04

Family

ID=8170594

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032531A NO20032531L (no) 2000-12-07 2003-06-04 Tetralon-derivater som antitumormidler

Country Status (25)

Country Link
US (1) US6531472B2 (no)
EP (1) EP1349830A1 (no)
JP (1) JP4091431B2 (no)
KR (1) KR20030077551A (no)
CN (1) CN100340545C (no)
AR (1) AR035659A1 (no)
AU (2) AU2002216074C1 (no)
BG (1) BG107889A (no)
BR (1) BR0115988A (no)
CA (1) CA2430355A1 (no)
CZ (1) CZ20031833A3 (no)
EC (1) ECSP034642A (no)
HR (1) HRP20030451A2 (no)
HU (1) HUP0400579A2 (no)
IL (1) IL156133A0 (no)
MA (1) MA26972A1 (no)
MX (1) MXPA03004947A (no)
NO (1) NO20032531L (no)
NZ (1) NZ526051A (no)
PL (1) PL365324A1 (no)
RU (1) RU2288220C2 (no)
SK (1) SK8512003A3 (no)
WO (1) WO2002046144A1 (no)
YU (1) YU45803A (no)
ZA (1) ZA200304262B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
NZ550185A (en) 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
AU2003226014A1 (en) * 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US8673888B2 (en) * 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20060247192A1 (en) * 2002-12-05 2006-11-02 Jenkinson John D Control of apoptosis
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
EP1663194B1 (en) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
JP2007504131A (ja) 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1734999A2 (en) * 2004-04-05 2006-12-27 Myogen, Inc. Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
WO2005099747A1 (en) * 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
KR100632800B1 (ko) 2004-10-21 2006-10-16 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
ZA200800901B (en) * 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2649877A1 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10184933B2 (en) 2013-10-01 2019-01-22 The J. David Gladstone Industries Compositions, systems and methods for gene expression noise drug screening and uses thereof
EP3062783B1 (en) 2013-10-18 2020-08-12 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
TWI799691B (zh) * 2019-03-29 2023-04-21 景凱生物科技股份有限公司 具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
EP4504165A1 (en) 2022-04-05 2025-02-12 Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
WO2025026925A1 (en) 2023-07-28 2025-02-06 Ospedale San Raffaele S.R.L. Gtf2i inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448730A (en) * 1981-03-24 1984-05-15 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5637946A (en) * 1993-10-28 1997-06-10 Lockheed Corporation Thermally energized electrical power source
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds

Also Published As

Publication number Publication date
IL156133A0 (en) 2003-12-23
NZ526051A (en) 2004-12-24
AR035659A1 (es) 2004-06-23
NO20032531D0 (no) 2003-06-04
CZ20031833A3 (cs) 2004-02-18
YU45803A (sh) 2006-05-25
BG107889A (bg) 2004-06-30
JP4091431B2 (ja) 2008-05-28
BR0115988A (pt) 2004-01-13
AU2002216074B2 (en) 2006-01-05
WO2002046144A1 (en) 2002-06-13
HUP0400579A2 (hu) 2004-06-28
PL365324A1 (en) 2004-12-27
RU2288220C2 (ru) 2006-11-27
CA2430355A1 (en) 2002-06-13
US6531472B2 (en) 2003-03-11
MXPA03004947A (es) 2003-09-10
AU1607402A (en) 2002-06-18
KR20030077551A (ko) 2003-10-01
MA26972A1 (fr) 2004-12-20
CN1478072A (zh) 2004-02-25
ZA200304262B (en) 2004-08-30
HK1060875A1 (en) 2004-08-27
EP1349830A1 (en) 2003-10-08
HRP20030451A2 (en) 2005-04-30
US20020065282A1 (en) 2002-05-30
ECSP034642A (es) 2003-07-25
AU2002216074C1 (en) 2006-12-07
JP2004515488A (ja) 2004-05-27
SK8512003A3 (en) 2004-04-06
CN100340545C (zh) 2007-10-03

Similar Documents

Publication Publication Date Title
YU45803A (sh) Tetralon derivati kao sredstva protiv tumora
Snieckus et al. Intramolecular. alpha.-amidoyl-to-aryl 1, 5-hydrogen atom transfer reactions. Heteroannulation and. alpha.-nitrogen functionalization by radical translocation
DE60304059D1 (de) 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs
MXPA04005350A (es) Compuesto de dibencilamina, y uso medicinal del mismo.
NO973198L (no) Aryl- og heteroarylpurinforbindelser
MY131297A (en) Herbicides
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
YU20199A (sh) Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora
NO980154L (no) Sykliske GMP-spesifikke fosfodiesteraseinhibitorer
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
HUP0002353A2 (hu) IV típusú foszfodiészteráz inhibitor hatású 1-cikloalkil-1,8-naftiridin-4-on-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
GB1457385A (en) Substituted formamidines process for their preparation and their use as uv stabilisers
BR0308785A (pt) Derivados de alcoxipiridina
PL1601653T3 (pl) Sposób wytwarzania podstawionych estrów kwasu nikotynowego
DK534381A (da) Fremgangsmaade til fremstilling af 2-oxoazetidinderivater
DK0656001T3 (da) Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
ES8206462A1 (es) Un metodo para preparar derivados de 2-oxoazetidina.
GB1428226A (en) Process for the prepataion of aromatic hydroxylamines in the presence of catalysts
GB1458753A (en) Process for the preparation of aromatic hydroxylamines by hydro genation of aromatic nitro derivatives
ES2101887T3 (es) Procedimiento microbiologico para la hidroxilacion de acidos carboxilicos con heterociclo nitrogenado.
ES419661A1 (es) Un procedimiento de preparacion de hidrazonas.
GB1054655A (no)
MX9800705A (es) Compuestos heterociclicos, composiciones para tratar isquemia de miocardio que los contiene, y procedimiento para su preparacion.
NO955071D0 (no) abeo-Ergolin-derivater som 5HT1A-ligander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application